Send me a link:

*Text messaging rates may apply.

 Dow Down1.88% Nasdaq Down2.09%

More On OXB.L

Quotes

Charts

News & Info

Company

Analyst Coverage

Ownership

  • Major Holders
  • Insider Transactions
  • Insider Roster

Financials


Oxford BioMedica PLC (OXB.L)

-LSE
2.88 Down 0.05(1.54%) 6:46AM EDT
ProfileGet Profile for:
Oxford BioMedica PLC
Medawar Centre
Robert Robinson Avenue
Oxford, OX4 4GA
United Kingdom - Map
Phone: 44 18 6578 3000
Fax: 44 18 6578 3001
Website: http://www.oxfordbiomedica.co.uk

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:106

Business Summary 

Oxford BioMedica plc, a biopharmaceutical company, develops gene-based medicines and therapeutic vaccines for the treatment of cancer, and age-related or inherited neurodegenerative disorders and ocular diseases. Its LentiVector gene delivery technology platform targets non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes. The company is developing ProSavin, which has completed Phase I/II trials for the treatment of Parkinson's disease; RetinoStat that is in Phase I trial for ‘wet’ age-related macular degeneration; StarGen, which is in Phase I/IIa trial for the treatment of Stargardt disease; UshStat that is in Phase I/IIa trial for Usher syndrome type 1B; EncorStat, which is Phase I/II trial preparation for the prevention of corneal graft rejection; and Glaucoma-GT, which is in pre-clinical stage for the treatment of chronic glaucoma. It is also developing TroVax that is in Phase II trial for colorectal cancer and mesothelioma; and Anti-5T4 antibody, which is in pre-clinical stage for the treatment of cancer. In addition, the company is developing MoNuDin for the treatment of motor neuron disease. It has collaborations and licensing agreements with Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, and ImaginAb. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Oxford BioMedica PLC

Key Executives 
 PayExercised
Mr. John Dawson , 54
Chief Exec. Officer and Director
N/AN/A
Mr. Timothy William Watts , 56
Chief Financial Officer, Company Sec. and Director
280.00KN/A
Mr. Peter Nolan , 61
Sr. VP of Commercial Devel. and Exec. Director
N/AN/A
Lara Mott ,
Head of Corp. Communications
N/AN/A
Dr. James Miskin Ph.D.,
Head of Manufacturing Devel.
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in GBp.